Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus NUVESSA.
Head-to-head clinical analysis: ETHINYL ESTRADIOL AND NORELGESTROMIN versus NUVESSA.
ETHINYL ESTRADIOL AND NORELGESTROMIN vs NUVESSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release via negative feedback on pituitary; progestin (norelgestromin) thickens cervical mucus and inhibits ovulation.
NUVESSA (bupivacaine liposomal) is a local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. The liposomal formulation provides sustained release of bupivacaine.
One transdermal patch (releasing 0.035 mg ethinyl estradiol and 0.150 mg norelgestromin per 24 hours) applied once weekly for 3 weeks, followed by 1 week patch-free.
5 mg orally once daily.
None Documented
None Documented
Ethinyl estradiol has a terminal elimination half-life of approximately 13-27 hours (mean ~17 hours). Norelgestromin has a terminal half-life of about 28 hours. These half-lives support once-weekly dosing of the transdermal system, achieving steady-state by the second application.
Terminal elimination half-life is approximately 24 hours (range 18-30 hours) in healthy adults. This supports once-daily dosing; however, half-life may be prolonged in patients with renal impairment.
Ethinyl estradiol and norelgestromin are excreted primarily via urine and feces. Ethinyl estradiol undergoes extensive metabolism; about 40% is excreted in urine and 60% in feces as glucuronide and sulfate conjugates. Norelgestromin is metabolized to norgestrel and other metabolites; approximately 45% is excreted in urine and 35% in feces.
Primarily renal excretion of unchanged drug and metabolites (approximately 70% of the dose), with about 20% eliminated via biliary/fecal routes. Less than 10% is recovered as unchanged drug in urine.
Category D/X
Category C
Estrogen
Estrogen